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Abstract: Polyunsaturated fatty acids (PUFAs) are necessary for overall health. 
Two PUFAs families, n-6 and n-3 fatty acids, are physiologically and metabo-
lically distinct. The proportion of PUFAs in serum and erythrocyte phospho-
lipids, which depends on endogenous metabolism controlled by genetic poly-
morphisms and dietary intake, is an important determinant of both health and 
disease. Both n-3 and n-6 PUFAs are processed to powerful promoters of eico-
sanoids synthesis at the cyclooxygenase and lipoxygenase level. Evidence from 
observational and intervention studies suggest that n-3 PUFAs are cardio-
protective, perhaps through their anti-inflammatory, anti-arrhythmic, lipid-low-
ering and antihypertensive effects. In contrast, dietary n-6 PUFAs have pro-
inflammatory effects. Low n-3 and elevated n-6 PUFAs levels were found in 
patients with cancer on different sites. The present review focuses on current 
knowledge related to PUFAs intake and status in health and disease, with refe-
rence to the Serbian population.  
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4. CONCLUSIONS 
1. INTRODUCTION 
Polyunsaturated fatty acids (PUFAs) play important roles in maintaining 
normal physiological conditions and, consequently, in human health. Two 
PUFAs families, n-6 and n-3 fatty acids (FA), are physiologically and metaboli-
cally distinct. Their precursors, linoleic acid (18:2n-6; LA) and α-linolenic acid 
(18:3n-3; ALA) are essential fatty acids (EFA), meaning that they cannot be syn-
thesized in the human body and must be obtained from the diet. Thus, LA can be 
converted via γ-linolenic acid (18:3n-6) and dihomo-γ-linolenic acid (20:3n-6; 
DGLA) to arachidonic acid (20:4n-6; AA) (Fig. 1). Arachidonic acid plays 
important biological roles. It is released from phospholipids by phospholipase A2 
and is the precursor of pro-inflammatory eicosanoids, which include prostaglan-
dins of the two series (PGE2, PGD2), leukotrienes of the four series (LTA4, 
LTB4, LTC4, LTD4 and LTE4) and lipoxines.1 Their production is catalyzed by 
cyclo-oxygenase, lipoxygenase and epoxygenase enzymes, respectively. By an 
analogous set of reactions catalyzed by the same enzymes, precursor of n-3 
PUFAs, ALA, can be converted into eicosapentaenoic acid (20:5n-3; EPA), and 
further to docosapentaenoic acid (22:5n-3; DPAn-3) and docosahexaenoic acid 
(22:6n-3; DHA). This is achieved by insertion of additional double bonds into the 
acyl chain (i.e., unsaturation) and by elongation of the acyl chain. EPA is a pre-
cursor of the other classes of eicosanoids, namely the three series of prostaglan-
dins and the five series of leukotrienes. Eicosanoids derived from AA have oppo-
sing properties from those originating from EPA. Therefore, an increase in the 
dietary intake of LA changes the physiological state to a prothrombotic, procons-
trictive, and pro-inflammatory one. Many of the chronic conditions, cardiovas-
cular disease, diabetes, cancer, obesity, auto-immune diseases, rheumatoid arth-
ritis, asthma and depression are associated with an increased production of thro-
mboxane A2, leukotriene B4, IL-1, IL-6, tumour necrosis factor (TNF), and C-
reactive protein.2,3 All these factors are increased by increased n-6 PUFAs intake 
and decreased by increased n-3 PUFAs intake, either ALA or EPA and DHA. 
However, there is one exception. DGLA of the n-6 family can be further con-
verted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and 
PGE1. This is interesting because these compounds possess anti-inflammatory 
and anti-proliferative properties. PGE1 could also induce growth inhibition and 
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differentiation of cancer cells.4 The mechanism of DGLA action has not yet been 
elucidated. 
 
Fig. 1. Dietary sources, metabolism of n-3 and n-6 PUFAs and clinical outcomes. 
It is well known that PUFAs favourably affect the blood lipid profile (Table 
I). LA is associated with a lower risk of atherosclerosis, cardiovascular heart 
disease (CHD) and type 2 diabetes.5–8 Consumption of ALA has also been sug- 
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TABLE I. Potential beneficial effects of PUFA on physiological parameters6,7,9,11 
Total PUFA Diseases Physiological parameters 
ALA Cancer/coronary heart 
disease 






↓Serum total cholesterol 
↓Platelet aggregation, adhesion of monocytes to 
vessel walls, vascular dilatation, blood pressure, 
inflammatory processes, and immune reaction 
↑Leukocyte function 
↑Neural integrity n-3 deficiency in pre- and 
postnatal nutrition of infants affects: neural 
integrity, learning and visual abilities and depressed 











↓Production of PGE2 metabolites 
↓Thromboxane A2, a potent platelet aggregator and 
vasoconstrictor 
↓Leukotriene B4 formation, an inducer of inflam-
mation, and a powerful inducer of leukocyte 
chemotaxis and adherence 
↑Thromboxane A3, a weak platelet aggregator and 
weak vasoconstrictor 
↑Prostacyclin PGI3, leading to an overall ↑ in total 
prostacyclin by ↑ PGI3 without a ↓ PGI2, both PGI2 
and PGI3 are active vasodilators and inhibitors of 
platelet aggregation 
↑Leukotriene B5, a weak inducer of inflammation 
and a weak chemotactic agent 
↓Serum triglycerides, VLDL-C 
↓Platelet aggregation, adhesion of monocytes to 
vessel walls, vascular dilatation, blood pressure, 
inflammatory processes, and immune reaction 
↑Rod photoreceptor, visual acuity, neural function 
(infants) 
LA CVD mortality 
Deficiency disease 
↓Serum total cholesterol, LDL-C, HDL-C 
↑Platelet aggregation, adhesion of monocytes to 
vessel walls, vascular dilatation, blood pressure, 
inflammatory processes, and immune reaction 
gested to reduce the risk of CHD events.9–12 Nevertheless, clinical benefits have 
not been confirmed in all studies, and further research on the association between 
ALA consumption and the incidence of CHD are required. The long chain n-3 
PUFAs, EPA and DHA, consumption have demonstrated physiological benefits 
on blood pressure, heart rate, triglycerides, likely inflammation, endothelial func-
tion, and cardiac diastolic function.13–16 Furthermore, consistent evidence for a 
decreased risk of fatal CHD and sudden cardiac death at consumption of > 250 
mg day–1 of EPA plus DHA were also reported.17 For primary prevention of car-
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diac arrest, minimum intakes of 250 mg day–1 of marine EPA and DHA have 
been suggested.14 
DHA also plays a major role in cognitive functions. Therefore, its intake is 
very important during pregnancy, in young children but also in the elderly. DHA 
is involved in normal development of the brain and retina during foetal develop-
ment and the first 2 years of life.18–20 In healthy children a positive associations 
between DHA levels in blood and improvements on tests of cognitive and visual 
function was found.21 A study in human adults using positron emission tomo-
graphy showed that a normal human brain consumes around 17.8 and 4.6 mg 
day–1 of AA and DHA, respectively, and that brain AA consumption is increased 
in Alzheimer disease patients.22 In addition, some clinical evidence suggests that 
an AA/DHA ratio greater than 1/1 is associated with improved cognitive out-
comes.23 These findings suggest that recommendations for adequate intakes of 
DHA and other PUFAs in pregnant women, young children and elderly are 
urgently needed. The present review focuses on the current knowledge related to 
PUFAs intake and status in health and disease, with reference to the Serbian 
population. 
2. PUFAs INTAKE AND STATUS 
2.1. Dietary sources 
LA is present in significant amounts in many vegetable oils, including corn, 
sunflower, grape seed and soybean oils, and in products made from these oils, 
such as margarines. ALA is found in green plant tissues, in some common vege-
table oils, including soybean and rapeseed oils, in some nuts and in particular in 
linseeds and linseed oil.24 Arachidonic acid is mostly present in meats and its 
intake is estimated at 50 to 500 mg day–1. The richest sources of EPA, DPA and 
DHA are oily fish (tuna, salmon, mackerel, herring, and sardine). One oily fish 
meal can provide between 1.5 and 3.5 g EPA+DHA.25 Consumption of 1 g fish 
oil capsule per day can provide about 300 mg of these fatty acids. In the absence 
of oily fish or fish oil consumption, the intake of n-3 PUFAs is likely to be 100 
mg day–1.26 According to habitual dietary information in Serbia, low fat con-
sumers have an intake of 5.4 % of daily energy intake (%E) and high fat con-
sumers around 5.9 % E from PUFAs.27 
2.2. n-6 to n-3 PUFAs ratio 
The intake of LA in western countries has increased greatly in the last few 
decades, due to the introduction and marketing of cooking oils and margarines.28 
Typical intakes of both EFA exceed requirements. However, replacing lard with 
sunflower oil in the diet has resulted in a marked increase in the ratio of n-6 to n-3 
PUFAs. This ratio is typically between 5 and 20 in most Western populations.29 
A lower n-6 to n-3 PUFAs ratio consumption has been recommended in order to 
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reduce the formation of pro-inflammatory eicosanoids from n-6 PUFAs and to 
increase the production of anti-inflammatory mediators from n-3 FA.2,30 Addi-
tionally, it was suggested that lowering the n–6 FA intake would have the same 
health effects as increasing n-3 FA intake. Wall et al.31 recently reviewed that 
reductions in the n-6 to n-3 FA ratio in the diet may lower the incidence of many 
chronic diseases that involve inflammatory processes; these include cardiovas-
cular diseases, inflammatory bowel disease, cancer, rheumatoid arthritis and psy-
chiatric and neurodegenerative illnesses. Thus, the specific n-6/n-3 ratio in the 
diet is of particular interest for maintaining overall health.  
2.3. Recommendations for intake of PUFAs  
In the light of new evidence for associations between low intakes of some 
PUFAs and increased risk of chronic disease that was mentioned above, optimal 
criteria for dietary recommendation aim to achieve optimal health and to reduce 
risk of developing chronic disease.32 A World Health Organization report from 
199433 did not suggest nutrient intake values for total PUFAs, but focused on the 
ratio of LA/ALA in the diet. Recent reports indicated that in healthy adults, the 
minimum intake levels for EFA should be 2.5 % LA plus 0.5 % ALA of daily 
energy intake to prevent deficiency symptoms.32 Recommendations on the intake 
of PUFAs in healthy adults from Nutrition bodies and International Dietary 
Recommendations32–40 are listed in Table II. An effective intake for the preven-
tion of chronic diseases is higher, 6–11 % E, which is considered as the optimal 
range for the total intake of PUFAs.2,32,40 Currently, there is no upper n-6 
PUFAs value in the Eurodiet core report.39 These different positions reflect the 
current worldwide debate on the relevance of an upper limit in dietary n-6 PUFA 
intake and highlight the need for further in vivo investigations. At the moment, 
the nutrition body supports the recommendation for n-6 PUFA intake above 5 %, 
and ideally about 10 % of total energy. However, balance in the n-6/n-3 ratio 
issue was debated in detail by Stanley et al.41 and Harris,42 who concluded that 
this ratio is not relevant for setting up recommendations. Based on both evidence 
and conceptual limitations, there is no compelling scientific rationale for the con-
tinued recommendation of a specific ratio of n-6 to n-3 PUFAs or LA to ALA. 
2.4. PUFAs intake in relation to status biomarker  
The proportion of PUFAs in serum and erythrocyte phospholipids, an impor-
tant determinant of both health and disease, depends on the dietary intake and 
endogenous metabolism controlled by genetic polymorphisms. The FA compo-
sition of serum phospholipids is genetically controlled by the FADS1 and 
FADS2 gene cluster. Based on this genetic variation, individuals may require dif-
ferent amounts of dietary PUFAs to achieve comparable biological effects.43 
Nevertheless, the FA composition in serum lipids can be used not only as a bio-
marker of fat quality intake, but also as an indicator of disease risk. 
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PUFAs are important constituents of the phospholipids of all cell mem-
branes. LA, ALA and their metabolic products, AA, EPA and DHA are crucial 
structural and functional components of cellular and intracellular membranes in 
the human body, but especially in brain, heart, retina, and testes. Phospholipids 
play an essential role in membrane structure and function. PUFAs of both the n-6 
and n-3 series are incorporated into membrane phospholipids, and the AA/EPA 
ratio ranges between 1:1 and 5–10:1. The higher ratio stimulates the incorpora-
tion of EPA, because of the greater affinity of enzymes for EPA.44 The length 
and degree of unsaturated FAs in membrane phospholipids are the main deter-
minants of fluidity, transport systems, activity of membrane-bound enzymes, and 
susceptibility to lipid peroxidation.45–47 In this context, an altered FA composi-
tion with reduced levels of PUFAs and increased contents of saturated FA (SFA), 
that consequently decrease the PUFA/SFA ratio in erythrocyte membranes, may 
be associated with lower membrane fluidity in patients with chronic diseases.48,49 
This is often found in elite athletes.50–52  
It was previously established that erythrocytes reflect the general FA meta-
bolism in other organs and tissues.53,54 A poor n-3 PUFAs status is often related 
to a low consumption of cold-water fish, as the primary source of EPA and DHA, 
and then to income status, national and social eating habits. However, an inade-
quate EFA intake is not the only cause for a disturbance in the FA profile. EFA 
deficiency is also present in chronic inflammatory conditions,55 increased oxida-
tive stress related to PUFAs oxidation56 and in elevated intracellular calcium 
concentration.57 A number of studies showed that different pathologies, such as 
cancer, diabetes, coronary heart disease, pancreatitis, etc., could be associated to 
altered FA profiles of plasma or serum phospholipids.58–61 Patients with renal 
failure, liver cirrhosis or diabetes mellitus often have plasma FA profiles similar 
to those with nutritional deficiency of EFA.62–65 Considering limited storage of 
n-3 FA in adipose tissue in both patients and healthy people, a continued dietary 
supply with the optimal n-6/n-3 ratio of PUFAs has been suggested. A diet sup-
plemented with n-3 PUFAs partially replace n-6 PUFAs in the majority of the 
membranes of cells (e.g., erythrocytes, platelets, monocytes, lymphocytes and 
granulocytes, and endothelial neuronal, colon, and hepatic cells), suggesting that 
in spite of pathologies, diet could markedly change the FA profiles in patients.  
In the Serbian population with type 2 diabetes59 who also had abnormal lipid 
levels, the total n-3 PUFAs in plasma were lower, while the n-6/n-3 ratio was 
higher when compared to healthy subjects (Table III). EPA, DHA and total n-3 
PUFAs in the erythrocyte phospholipids in these patients59 were also low (Table 
IV). Patients with hyperlipidemia60 had a significantly lower proportion of EPA 
and DHA than healthy subjects. Suboptimal levels of n-3 FA in erythrocytes 
have been found in obese subjects,67 as well as a lower proportion of EPA, DHA 
and total n-3 FA, and a significantly higher n-6/n-3 ratio in insulin-resistant 
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obese women when compared to obese women with normal glucose tolerance 
(Table IV). A similar n-3 FA status in serum phospholipids and red blood cells 
was reported in well-nourished patients62 undergoing haemodialysis. Proportions 
of DHA and n-3 PUFAs in serum phospholipids of patients with non-Hodgkin 
lymphoma,61 as well as in patients with obstructive jaundice66 were extremely 
low, which led to very high n-6/n-3 ratios of around 15 in both groups of patients, 
demonstrating a complete imbalance of FA in these patients. However, the n-6/n-3 
ratio in healthy subjects in the Serbian population was also very high (11–12), 
suggesting the importance of changing dietary habits in Serbia.50–52,61,62 
TABLE III. Plasma phospholipids fatty acids composition (mol %) with reference to the 
Serbian population; HLP, hyperlipidemic patients; DM, diabetes mellitus; HD, haemodialyses 
patients; NHL, patients with non-Hodgkin lymphoma 
Serum 
Healthy controls 
(n = 27)62 
HLP 
(n = 41)60
DM 2, HLP 
(n = 29)59 
Obstructive jaun-
dice (n = 13)66 
HD 
(n = 29)62 
NHL 
(n = 47)61 
LA 26.5±2.8 23.1±1.4 22.6±2.4 24.8±3.4 25.5±2.9 20.2±2.4 
DGLA 2.4±0.7 3.0±0.4 3.0±0.8 2.6±1.0 2.0±0.5 3.9±1.0 
AA 11.6±2.3 11.4±1.0 13.2±2.9 8.8±1.50 11.1±2.2 14.3±1.5 
22:4 n-6 0.4±0.2 0.4±0.1 0.6±0.3 0.2±0.1 0.4±0.1 0.6±0.2 
Σn-6  40.8±2.9 38.0±1.7 39.5±3.4 35.6±3.2 39.0±3.3 38.8±2.6 
ALA 0.11±0.0152 0.10±0.02 – – – – 
EPA 0.4±0.1 0.3±0.05 0.4±0.3 0.35±0.07 0.3±0.1 0.2±0.1 
DPAn-3 0.6±0.1 0.5±0.1 0.6±0.2 0.35±0.10 0.5±0.1 0.4±0.2 
DHA 3.6±1.1 3.1±0.3 2.5±0.7 2.2±0.7 3.0±0.9 2.1±0.7 
Σn-3  4.7±1.4 4.0±0.3 3.5±0.8 2.6±0.8 3.8±1.2 2.7±0.7 
n-6/n-3 8.8±1.6 9.4±0.9 11.2±2.7 14.2±3.5 9.6±1.3 15.4±4.6 
3. BIOLOGICAL EFFECTS AND METABOLIC FUNCTIONS OF n-6 AND n-3 PUFAs 
An increasing body of evidence suggests that n–3 PUFAs supplementation may 
improve defects in insulin signaling and prevent alterations in glucose 
homeostasis and further development of diabetes type 2.63,68 These effects are pos-
sibly mediated through the peroxisome proliferator-activated receptors (PPARs), 
which are up-regulated by long-chain PUFA and in turn are related to the gene 
expression involved in lipid oxidation and synthesis.69 Other pleiotrophic effects 
of n–3 PUFAs may contribute to decreased condition of the metabolic syndrome, 
such as modulation of inflammation, platelet activation, endothelial function and 
blood pressure.70 
In addition, a high proportion of n-3 PUFAs in red blood cell membranes is 
associated with a reduced risk of primary cardiac arrest. The American Heart 
Association recommended that individuals at high cardiovascular risk should 
consume 1 g daily of fish oil.7,71 It was shown that n-3 PUFAs oral supplement-
ation quickly and effectively raised the blood n-3 PUFAs levels.72 However, 
some new data and meta analyses showed no effect of n-3 supplementation and 
___________________________________________________________________________________________________________________Available online at www.shd.org.rs/JSCS/
Copyright (C)2013 SCS
1278 RISTIĆ-MEDIĆ et al. 
 
___________________________________________________________________________________________________________________Available online at www.shd.org.rs/JSCS/
Copyright (C)2013 SCS
 PUFA IN HEALTH AND DISEASE 1279 
health benefits. Considering these facts, further work is required to confirm the 
association between plasma PUFAs levels and clinical outcomes. 
3.1. PUFAs and dyslipidemia 
One of the most investigated health effect of n-3 PUFA is their capability to 
reduce serum triglyceride levels. Many different mechanisms seem to be 
involved in the hypotriglyceridemic effect of n-3 PUFAs in humans. First, it is 
assumed that the lipid-altering effects of n-3 PUFA could modify gene expres-
sion.73,74 At the gene transcriptional level, they can act on liver X receptor, 
hepatocyte nuclear factor-4a, farnesol X receptor and PPAR-alpha and PPAR- 
-gamma. They simultaneously down-regulate genes encoding proteins that sti-
mulate lipid synthesis and up-regulate genes encoding proteins that stimulate 
fatty acid oxidation, both processes resulting in lower serum triglyceride 
levels.75–77 EPA and/or DHA supplementation in animal studies reduced the 
substrate for triglyceride synthesis and increased peroxisomal, mitochondrial FA 
β-oxidation78 and decreased concentrations of all blood lipids.79 These FA acti-
vate expressions of genes involved in β-oxidation controlled by PPAR-α recep-
tors. It was also reported that fish oil supplementation decreased the fractional 
catabolic rates of high density lipoprotein (HDL) and increased the ratio of HDL- 
-2/HDL-3 cholesterol.80 This was related to a decrease in the levels of plasma 
triglycerides, which stabilizes HDL particles as they become larger, retain more 
cholesterol and are less susceptible to catabolism by hepatic and renal clearance 
pathways.81 At the level of low density lipoprotein (LDL) cholesterol and very 
low density lipoprotein (VLDL), peroxidation of PUFAs stimulates apoB deg-
radation, reduces VLDL secretion, stimulates lipoprotein lipase activity mecha-
nisms and increases postprandial clearance.82,83 
The dosage of n-3 PUFA that lowers triglycerides differs among studies. 
Bays84 found that 4 g of n-3 PUFAs per day, in the form of fish oil capsules, 
reduced serum triglyceride levels by 35 to 45 %. In a meta-analysis of 72 ran-
domized control trials, Harris78 reported a serum triglyceride reduction of 25– 
–30 % at a dosage of 3–4 g day–1 of EPA + DHA. The effect of n-6 PUFAs 
enriched diets was also studied. A meta-analysis of 60 controlled trials reported 
that replacement of carbohydrates with PUFAs (largely n-6) had a beneficial 
effect on the total cholesterol/HDL-cholesterol ratio, and on the LDL concen-
tration.85 Replacing SFA by n-6 PUFAs also led to a substantial reduction in the 
total cholesterol and LDL-cholesterol, a reduction of the total cholesterol/HDL- 
-cholesterol ratio and thus may reduce the risk of CHD.86–88 A recently pub-
lished paper89 showed that the plasma cholesterol value was negatively corre-
lated with serum levels of EPA. 
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3.2. PUFAs and obesity and diabetes  
Although a favourable effect of n-3 PUFAs on development of diabetes 
mellitus was shown in several studies, the overall pooled data findings do not 
support any benefits of oily fish/seafood or EPA+DHA intake on diabetes and 
suggest that ALA may be associated with a modestly lower risk.90 However, 
some evidence indicates that higher proportion of n-3 PUFAs in the diet may 
have anti-obesity effects and protection against metabolic syndrome through a 
number of metabolic effects. 
It was proposed that n-6 PUFAs may be involved in the differentiation of 
preadipose cells to adipocytes.91,92 To date, no firm conclusion could be drawn 
from available in vitro studies93,94 on the role of AA in the differentiation of 
preadipose cells. Moreover, animal studies investigating the effect of a diet 
enriched in n-6 PUFAs on adipose tissue produced conflicting results.91,94–96 
More research is required to ascertain whether a balance of n-3 and n-6 in the 
diet contributes to excessive development of adipose tissue.  
3.3. PUFAs and inflammation response  
The possible mechanisms in PUFAs modulation of inflammatory response 
were investigated in a number of studies but the data were often inconsistent. 
Based on preclinical studies, the underlining mechanisms include transcriptional 
down-regulation of the production of pro-inflammatory cytokines,97 cyclooxyge-
nase-2 activity,98 and vascular surface expression of endothelial leukocyte adhe-
sion molecules.99 These effects are a consequence of altered gene expression. 
Animal studies showed that n-3 PUFAs supplementation inhibited the production 
of pro-inflammatory cytokines IL-1 and TNF.100 Similar observations were 
reported in studies in humans. In particular, studies of fish oil supplementation in 
patients with active inflammation diseases, such as rheumatoid arthritis and 
Crohn’s disease,100 supported a potentially beneficial anti-inflammatory effect of 
n-3 PUFAs. Dietary supplementation with n-3 PUFAs in healthy subjects was 
associated with reduced levels of IL-1, thromboxane 2 and prostaglandin 
E2,101,102 but not of C-reactive protein.103  
A potential protective effect of PUFAs supplementation on the progression 
of renal disease based on its action on inflammation in the renal fibrosis process, 
was suggested in studies on animal models.104 The actions of PUFAs interfere 
directly with mesangial cell activation and proliferation and extra-cellular matrix 
protein synthesis, and they are involved in the regulation of pro-inflammatory 
cytokine production.105,106 It is possible that PUFAs suppress the activity of the 
angiotensin-converting enzyme, reduce angiotensin II formation, enhance endo-
thelium nitric oxide generation, and down-regulate the expression of the trans-
forming growth factor-β (TGF-β).107 
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The anti-inflammatory effects of n-3 fatty acids from seafood may contribute 
to their protective actions towards atherosclerosis, plaque rupture and cardiovas-
cular mortality. In inflammatory bowel diseases, some trials reported improved 
gut histology, duration of morning stiffness, global assessments of pain, decreased 
disease activity, use of corticosteroids and relapse.108 However, the therapeutic 
dose of n-3 PUFA has not yet been established.109 For instance, reduction of pro-
inflammatory eicosanoids and cytokines could be achieved with an intake of 2–4 
g day–1 of 84 % EPA+DHA ethyl esters.110 In the inCHIANTI study,111 the 
intake of 7 g day–1 PUFAs led to higher plasma levels of AA and n-3 PUFA 
(mainly DHA) and these FA profiles were independently associated with lower 
levels of serum pro-inflammatory markers. Thies et al.112 reported that a dietary 
supplementation with moderate amounts of long-chain n-6 or n-3 PUFAs neither 
significantly affected inflammatory cell numbers nor neutrophil and monocyte 
responses.  
3.4. PUFAs and oxidative stress 
Both n-3 and n-6 PUFAs are highly susceptible to oxidation because of their 
multiple double bonds. This lipid peroxidation, leading to pro-inflammatory 
oxidised LDL and HDL, is highly suspected of contributing to the pathogenesis 
of atherosclerosis. Several studies showed that dietary supplementation of n-6 
PUFAs increased the extent of LDL oxidation in vitro compared with a diet 
enriched in mono-unsaturated FA.113 In contrast, markers related to LDL oxi-
dation in vitro or malondialdehyde derived from LDL showed no correlation with 
n-6 PUFA intake in a group of healthy volunteers.114 Furthermore, a double-
blind controlled intervention in a cohort of healthy men showed that fish oil con-
sumption combined with a high LA intake (21 g day–1) did not raise the plasma 
level of oxidised LDL compared with the same fish oil consumption but com-
bined with a low level of LA.115 Parameters of oxidative stress were significantly 
improved after fish oil supplementation in an animal study.79 EPA and DHA 
have beneficial effects in glomerular disease, which are attributed to their effect 
on the pro-oxidant and antioxidant status and EFA metabolism, as reviewed by 
Das.107 However, recent evidence does not support the idea that n-3 PUFAs up-
regulate oxidative stress. Further investigations would enable more definitive 
conclusions to be made.  
3.5. PUFAs and blood pressure and mortality 
As highlighted by a review of cross-sectional studies, an increase in the 
dietary intake of n-6 PUFAs is often associated with a decrease in blood pres-
sure.116 It was also reported that plasma levels of LA were inversely associated 
with systolic and diastolic blood pressures.117 Combining the results from diffe-
rent studies in a meta-analysis, Morris et al.118 found that at supraphysiological 
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doses of 5.6 g n-3 PUFAs in hypertensive subjects, systolic pressure was reduced 
by 3.4 and diastolic pressure by 2.0 mmHg. Possible mechanisms include modu-
lation of the biosynthesis of eicosanoids: hydroxyeicosatetraenoates or epoxy-
eicosatrienoates.119 A more recently published meta-analysis also supported the 
antihypertensive effects of n-3 PUFAs.120 Similar findings were obtained in animal 
models and cell culture studies, which indicate that n-3 PUFAs supplementation 
can lower blood pressure and proteinuria, potentially by the vasorelaxation action 
of n-3 PUFAs with increased endothelium-derived releasing factor107 and by 
having effects on TGF-β, renin, fibronectin and nitric oxide synthesis.104 
Another meta-analysis of 25 case–control studies was performed by Harris et 
al.121 in order to assess the association between the tissue contents of n-3 and n-6 
PUFAs and CHD events. They found that content of LA in tissue was signifi-
cantly decreased in patients with CHD events. Similar results were found in a 
study by Block et al.122 on the relation between acute coronary syndrome and the 
fatty acid content of whole-blood cell membranes. The renal, cardiovascular and 
reduced mortality benefits of n-3 fatty acids are still areas of active investigation. 
Kutner et al.123 in a prospective cohort study showed that dialysis patients with a 
high intake of fish live longer, with an approximately 50 % lower rate of mor-
tality over 3 years. Regarding the role of n-3 PUFAs and CVD, a randomized 
clinical trial by Svensson et al.124 found that compared with placebo groups, 
patients receiving n-3 PUFAs supplementation (1.7 g day–1) had a protective 
effect on the rate of myocardial infarctions but led to no improvement in the pri-
mary end point of total cardiovascular events and death, with a follow-up of 2 
years. The same authors reported that there was no change in heart rate vari-
ability in haemodialyzed patients during 8 weeks of n-3 PUFA supplementation 
at a dosage of 1.7 g day–1.125 A recently published controlled study by Kirke-
gaard et al.126 showed an inverse association between the presence of arterial 
fibrillation and plasma DHA. This is very important because high risk of sudden 
cardiac death is often caused by arrhythmias. Finally, a new meta-analysis of 20 
clinical studies127 looking at the effects of n-3 PUFAs in patients at high risk for 
cardiovascular events showed that the supplements had no effect on hard clinical 
outcomes, including all-cause mortality, cardiac death, sudden death, myocard 
infarction or stroke. In the future, better-powered studies would need to be con-
ducted to resolve the relationship between n-3 PUFAs status and the mortality risk. 
3.6. PUFAs and haematological parameters 
The effect of fish oil supplementation and n-3 PUFAs on red blood cell 
deformability and aggregation has also been investigated.128,129 Findings from 
these studies suggest that n-3 PUFAs have antithrombotic, antiproliferative and 
anti-aggregatory platelet effects.130 These FAs can influence gene regulation by 
down-regulating gene expression of platelet-derived growth factors and suppress 
the platelet activating factor, a potent platelet aggregator and leukocyte acti-
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vator.81,131 n-3 DPA can be metabolised by lipoxygenase in platelets, to form 
11-hydroxy-7,9,13,16,19- and 14-hydroxy-7,10,12,16,19-DPA. It was also reported 
that n-3 DPA is effective (more than EPA and DHA) in the inhibition of aggre-
gation in platelets obtained from rabbit blood.132 The results from human studies 
are not conclusive, and further investigations are required to clarify the role of n-6 
PUFAs in susceptibility to thrombosis.  
3.7. PUFAs and cancer 
Data from epidemiological studies suggest that diets rich in n-6 PUFAs may 
be associated with cancer risk. Studies on patients with cancer at different sites 
have shown a poor n-3 FA status due to suboptimal intakes and possible meta-
bolic disturbances. Low proportions of n-3 PUFAs in plasma and/or erythrocytes 
phospholipids were found in pancreatic, lung and prostate cancer, and non-
Hodgkin lymphoma.61,133,134 All n-3 PUFAs were shown to be particularly 
depleted in advanced cancer patients, during chemotherapy and in cancer patients 
close to death. Additionally, low plasma n-3 fatty acids were associated with loss 
of skeletal muscle in these patients.135 
Considering all these findings, supplementation with EPA and DHA in pati-
ents suffering from cancer was the objective in many trials. Long chain n-3 
PUFA have inhibitory effects in tumour formation, probably through alteration of 
prostaglandins synthesis and inhibition of cell proliferation in colon and breast 
cancer.136 A beneficial effect of n-3 supplementation throughout antineoplastic 
therapy was confirmed through weight, lean body mass and treatment outcomes. 
In patients with pancreatic cancer, fish oil supplementation may prevent cache-
xia.137 In contrast, n-6 PUFAs have been associated with a greater capacity to 
induce tumour formation.136 As mentioned above, Western diet contains dispro-
portionally high n-6/n-3 PUFA ratios, which is thought to contribute to cancer. In 
favour of this assumption is the proportion of n-6 PUFA in cancer patients, which 
was found to be very high in patients with non-Hodgkin lymphoma. 
The nature of the anti-tumour effects of EPA are not clearly understood, but 
one of the mechanisms is competitive inhibition of the use of AA for the 
production of eicosanoids. Eicosanoids derived from AA have been associated 
with both tumour promotion and progression. EPA is also a potent angiogenesis 
inhibitor, which suppresses the production of crucial angiogenic mediators, 
namely: vascular endothelial growth factor, platelet-derived growth factor, cyclo- 
-oxygenase 2, nuclear factor kappa beta and nitric oxide.138  
4. CONCLUSIONS 
In conclusion, PUFAs have important roles in a wide range of physiological 
and pathologic processes. However, more conclusive relationships between 
PUFAs and metabolic pathways of insulin resistance, obesity, pancreatic and 
liver function, diabetic nephropathy, asthma clinical outcomes, mental health and 
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PUFAs supplementation in cachexia should be established. Future supplemen-
tation studies in larger, randomized control trials are required to reveal the full 
potential of PUFAs in the prevention and therapy of chronic diseases.  
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И З В О Д  
ПОЛИНЕЗАСИЋЕНЕ МАСНЕ КИСЕЛИНЕ У ЗДРАВЉУ И БОЛЕСТИ 
ДАНИЈЕЛА РИСТИЋ-МЕДИЋ, ВЕСНА ВУЧИЋ, МАРИЈА ТАКИЋ, ИВАНА КАРАЏИЋ и МАРИЈА ГЛИБЕТИЋ 
Центар изузетних вредности у области истраживања исхране и метаболизма, Институт за 
медицинска истраживања, Универзитет у Београду, Београд 
Полинезасићене масне киселине (ПMK) су неопходне за нормално функционисање 
организма. Двe ПMK фамилије, n-6 и n-3 масне киселине се физиолошки и метабо-
лички разликују. Удео ПMK у фосфолипидима серума и еритроцита је важан показатељ 
здравља и болести, и зависи од ендогеног метаболизма, који је контролисан генетским 
полиморфизмом, и уноса хране. И n-6 и n-3 ПМК су прекурсори за синтезу еикозаноида 
на циклооксигеназном и липооксигеназном нивоу. Опсервационе и интервентне студије 
указују да n-3 ПMK имају кардиопротективни ефекат, делујући анти-инфламаторно, 
анти-аритмогено, хиполипидемично и антихипертензивно. Насупрот томе, сматра се да 
n-6 ПMK имају про-инфламаторно дејство. Низак ниво n-3 и повишен удео n-6 ПMK је 
показан код пацијената са различитим типовима малигнитета. У оквиру овог рада дат је 
преглед најновијих сазнања о дијетарном уносу и биомаркерима статуса ПMK у промо-
цији здравља и превенцији болести, са посебним освртом на резултате у нашој попула-
цији. 
(Примљено 2. априла, ревидирано 15. априла 2013) 
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